Biogen BIIB Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.42B+5.9% | $1.34B-16.6% | $1.61B+5.1% | $1.53B+3.5% | $1.48B-9.4% | ||
| $801.1M+2.7% | $779.9M+2.1% | $763.7M+2.6% | $744.3M+5.0% | $708.9M+5.3% | ||
| $293.8M+1.0% | $290.8M-5.1% | $306.3M+0.9% | $303.7M+1.4% | $299.4M+2.8% | ||
| $413M+14.2% | $361.6M+165% | $136.3M+180% | -$170.1M+24.7% | -$225.8M-42.8% | ||
| —— | -$102.7M+22.5% | -$132.6M+18.4% | -$162.5M+15.5% | -$192.4M+13.5% | ||
| $10.5M-83.8% | $64.7M-36.4% | $101.7M-10.4% | $113.5M-15.4% | $134.1M-51.0% | ||
| $228.4M+33.5% | $171.1M+125% | $76.1M— | —— | —— | ||
| —— | -$248M-7.5% | -$230.68M-8.1% | -$213.35M-8.8% | -$196.03M-9.7% | ||
| —— | —— | —— | —— | —— | ||
| -$1.01B-5.3% | -$958.1M-28.1% | -$747.7M-66.7% | -$448.5M-399% | $149.8M+90.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $2.59B+17.5% | $2.2B-10.1% | $2.45B+15.9% | $2.12B-18.0% | $2.58B-10.2% | ||
| $167.9M+9.2% | $153.8M+3.1% | $149.2M+8.1% | $138M-4.8% | $144.9M-5.7% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | -$40.1M+30.3% | -$57.5M-3.4% | -$55.6M— | ||
| $21.6M-31.6% | $31.6M-25.3% | $42.3M-68.0% | $132M-6.4% | $141.1M-31.5% | ||
| -$42.9M0.0% | -$42.9M-116% | -$19.9M-162% | $32M+662% | $4.2M-10.6% | ||
| —— | —— | —— | —— | $0— | ||
| -$1.53B-11.8% | -$1.37B-768% | -$158M+87.9% | -$1.3B-67.1% | -$780.5M+2.3% | ||
| —— | —— | —— | —— | —— | ||
| $291.2M+3.6% | $281.2M+97.3% | $142.5M+3,132% | -$4.7M+21.7% | -$6M— | ||
| -$322.7M-6.9% | -$301.9M-83.1% | -$164.9M-299% | -$41.3M+85.0% | -$274.8M+60.3% | ||
| $52.8M-49.8% | $105.1M+273% | $28.2M-60.1% | $70.6M+785% | -$10.3M+84.8% | ||
| —— | —— | $2.14B— | —— | —— | ||
| $297M+23.3% | $240.8M+14.5% | $210.3M+5.3% | $199.7M-15.8% | $237.3M+3.2% | ||
| —— | —— | —— | —— | —— | ||
| $27.1M-8.4% | $29.6M-37.7% | $47.5M-33.8% | $71.8M-12.1% | $81.7M-19.8% | ||
| —— | $52.9M+33.3% | $39.68M+50.0% | $26.45M+100% | $13.23M— | ||
| -$89.6M-31.2% | -$68.3M+40.0% | -$113.8M-2.9% | -$110.6M+21.5% | -$140.9M+11.7% | ||
| —— | $85M+33.3% | $63.75M+50.0% | $42.5M+100% | $21.25M— | ||
| -$42.9M0.0% | -$42.9M-116% | -$19.9M-162% | $32M+662% | $4.2M-10.6% | ||
| —— | —— | —— | —— | $0— | ||
| $21.6M-31.6% | $31.6M-25.3% | $42.3M-68.0% | $132M-6.4% | $141.1M-31.5% | ||
| —— | $0-100% | $101.7M-50.0% | $203.4M-33.3% | $305.1M-25.0% | ||
| —— | —— | —— | —— | —— | ||
| $2.42B+18.1% | $2.05B-11.0% | $2.3B+16.5% | $1.98B-18.8% | $2.44B-10.5% | ||
| $2.42B+18.1% | $2.05B-11.0% | $2.3B+16.5% | $1.98B-18.8% | $2.44B-10.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Biogen generate?
- Biogen (BIIB) generated $2.6B in operating cash flow over the trailing twelve months.
- What is Biogen's free cash flow?
- After $167.9M of capital expenditures, Biogen's free cash flow was $2.4B over the trailing twelve months, down 0.6% year over year.
- Where does Biogen's cash flow data come from?
- Every line is extracted from Biogen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
